Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYChi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in ChinaPREV STORYCrownBio and Hubrecht Organoid Technology Announce a Strategic Partnership, including Exclusive License to Provide Oncology Organoid-Based Preclinical Drug Development and Validation Services